Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.45 -0.43 (-0.92%)
Official Closing Price Updated: 7:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
73 74 Next >
FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer
FDA approves Bristol-Myers Squibb and 2seventy Bio Abecma (ide-cel) for relapsed or refractory multiple myeloma after ≥2 prior therapies. Extends progression-free survival by 13.3 months vs. standard... 
Via Benzinga
Exposures Product Safety
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
From Bristol Myers Squibb
Via Business Wire
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
These stocks could rocket higher, but they also present significant risks. 
Via The Motley Fool
Is Bristol Myers Squibb Stock a Buy?
The company is going through a rough patch. 
Via The Motley Fool
Check Out What Whales Are Doing With BMY
Via Benzinga
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
From Bristol Myers Squibb
Via Business Wire
Merger Mania: 3 Potential Takeover Targets to Watch for Lucrative Buyouts
With interest rates poised to fall, acquisitions will become more numerous. Here are three potential takeover targets. 
Via InvestorPlace
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
From Bristol Myers Squibb
Via Business Wire
The Bargain Hunter’s Dream: 3 Underpriced Stocks Poised for Massive Gains
Uncover strategic moves by three pharma giants poised to capture trends and fulfill emerging healthcare needs. 
Via InvestorPlace
One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details
Bristol Myers Squibb shares update on Phase 3 YELLOWSTONE trial for Zeposia (ozanimod) in Crohn's disease. Primary endpoint not met, safety consistent. Also, positive Phase 3 results for Krazati... 
Via Benzinga
The 3 Best Biotech Stocks to Buy in Q2 2024
Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2. 
Via InvestorPlace
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
From Bristol Myers Squibb
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
Exposures Product Safety
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider. 
Via InvestorPlace
Merck's $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease
FDA approves Merck's Winrevair for PAH treatment. First-in-class therapy to enhance exercise capacity, improve WHO FC, and reduce clinical worsening. Available in select U.S. pharmacies by April.... 
Via Benzinga
Exposures Product Safety
Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
From Bristol Myers Squibb
Via Business Wire
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
From Bristol Myers Squibb
Via Business Wire
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Europe Approves Bristol Myers Squibb's CAR-T Therapy For Early Treatment Of Type Of Blood Cancer
The European Commission approved Bristol Myers Squibb's Abecma for relapsed/refractory multiple myeloma, making it the first CAR T cell therapy endorsed in the EU for earlier treatment lines. 
Via Benzinga
Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual... 
Via Benzinga
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel 
Via MarketBeat
Exposures Product Safety
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer... 
Via Benzinga
Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign
From Bristol Myers Squibb
Via Business Wire
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &... 
Via Benzinga
Exposures Product Safety
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
73 74 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.